These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 6103389

  • 1. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS.
    Lancet; 1980 May 17; 1(8177):1043-7. PubMed ID: 6103389
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
    Douglas DL, Duckworth T, Kanis JA, Preston C, Beard DJ, Smith TW, Underwood I, Woodhead JS, Russell RG.
    Arthritis Rheum; 1980 Oct 17; 23(10):1185-92. PubMed ID: 6448604
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.
    Delmas PD, Chapuy MC, Vignon E, Charhon S, Briancon D, Alexandre C, Edouard C, Meunier PJ.
    J Clin Endocrinol Metab; 1982 Apr 17; 54(4):837-44. PubMed ID: 6460781
    [Abstract] [Full Text] [Related]

  • 5. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
    Paterson AD, Kanis JA, Cameron EC, Douglas DL, Beard DJ, Preston FE, Russell RG.
    Br J Haematol; 1983 May 17; 54(1):121-32. PubMed ID: 6221750
    [Abstract] [Full Text] [Related]

  • 6. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP).
    Adami S, Guarrera G, Salvagno G, Spiazzi G, Marini G, Rosini S, Lo Cascio V.
    Metab Bone Dis Relat Res; 1984 May 17; 5(6):265-7. PubMed ID: 6238218
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate.
    Delmas PD, Chapuy MC, Meunier PJ.
    Horm Metab Res; 1984 May 17; 16(5):258-61. PubMed ID: 6234216
    [Abstract] [Full Text] [Related]

  • 9. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL, Goa KL.
    Drugs; 1994 Jun 17; 47(6):945-82. PubMed ID: 7521833
    [Abstract] [Full Text] [Related]

  • 10. Clodronate in the medical management of hyperparathyroidism.
    Hamdy NA, Gray RE, McCloskey E, Galloway J, Rattenbury JM, Brown CB, Kanis JA.
    Bone; 1987 Jun 17; 8 Suppl 1():S69-77. PubMed ID: 2961358
    [Abstract] [Full Text] [Related]

  • 11. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
    Chapuy MC, Charhon SA, Meunier PJ.
    Metab Bone Dis Relat Res; 1983 Jun 17; 4(6):325-8. PubMed ID: 6229683
    [Abstract] [Full Text] [Related]

  • 12. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC, Paterson AD, Yates AJ, Beard DJ, Douglas DL, Neal FE, Russell RG, Kanis JA.
    Br J Cancer; 1985 May 17; 51(5):665-9. PubMed ID: 3158326
    [Abstract] [Full Text] [Related]

  • 13. Drug treatment of primary hyperparathyroidism: use of clodronate disodium.
    Douglas DL, Kanis JA, Paterson AD, Beard DJ, Cameron EC, Watson ME, Woodhead S, Williams J, Russell RG.
    Br Med J (Clin Res Ed); 1983 Feb 19; 286(6365):587-90. PubMed ID: 6218861
    [Abstract] [Full Text] [Related]

  • 14. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
    Yates AJ, Percival RC, Gray RE, Atkins RM, Urwin GH, Hamdy NA, Preston CJ, Beneton MN, Russell RG, Kanis JA.
    Lancet; 1985 Jun 29; 1(8444):1474-7. PubMed ID: 2861411
    [Abstract] [Full Text] [Related]

  • 15. [Diphosphonates in the treatment of hypercalcemia].
    Delmas PD, Meunier PJ.
    Rev Med Interne; 1984 Nov 29; 5(4):363-6. PubMed ID: 6240753
    [Abstract] [Full Text] [Related]

  • 16. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
    Shane E, Jacobs TP, Siris ES, Steinberg SF, Stoddart K, Canfield RE, Bilezikian JP.
    Am J Med; 1982 Jun 29; 72(6):939-44. PubMed ID: 6211978
    [Abstract] [Full Text] [Related]

  • 17. Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease.
    Harris ST, Neer RM, Segre GV, Petkau AJ, Tully GL, Daly M, Potts JT.
    J Clin Endocrinol Metab; 1982 Dec 29; 55(6):1100-7. PubMed ID: 6215419
    [Abstract] [Full Text] [Related]

  • 18. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V.
    Bone Miner; 1994 May 29; 25(2):75-82. PubMed ID: 8086853
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
    Adami S, Salvagno G, Guarrera G, Montesanti F, Garavelli S, Rosini S, Lo Cascio V.
    Calcif Tissue Int; 1986 Oct 29; 39(4):226-9. PubMed ID: 2947663
    [Abstract] [Full Text] [Related]

  • 20. Dichloromethylene diphosphonate action in hematologic and other malignancies.
    Canfield RE, Siris ES, Jacobs TP.
    Bone; 1987 Oct 29; 8 Suppl 1():S57-62. PubMed ID: 2961356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.